Search the web
Welcome, Guest
[Sign Out, My Account]
 EDGAR_Online

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI 		Symbol Lookup | Financial Search
GTXI > SEC Filings for GTXI > Form 8-K on 11-Jun-2009All Recent SEC Filings

Show all filings for GTX INC /DE/ | Request a Trial to NEW EDGAR Online Pro

Form 8-K for GTX INC /DE/

11-Jun-2009

Other Events, Financial Statements and Exhibits


ITEM 8.01 Other Events.
On June 11, 2009, GTx, Inc. issued a press release announcing the results of a Phase II clinical trial evaluating Ostarine™ (MK-2866), an investigational selective androgen receptor modulator (SARM), in patients with cancer induced muscle loss, also known as cancer cachexia, a copy of which is furnished as Exhibit 99.1 to this Current Report.



ITEM 9.01 Financial Statements and Exhibits.
(c) Exhibits 

         Exhibit
         Number    Description
         99.1      Press Release issued by GTx, Inc. dated June 11, 2009

Table of Contents

  Add GTXI to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for GTXI - All Recent SEC Filings
Sign Up for a Free Trial to the NEW EDGAR Online Pro
Detailed SEC, Financial, Ownership and Offering Data on over 12,000 U.S. Public Companies.
Actionable and easy-to-use with searching, alerting, downloading and more.
Request a Trial      Sign Up Now

Copyright © 2010 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.